Virum, Denmark

Birgitte Møllgaard


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2007-2016

Loading Chart...
3 patents (USPTO):Explore Patents

Title: An Insight into the Innovations of Birgitte Møllgaard

Introduction

Birgitte Møllgaard, a talented inventor based in Virum, Denmark, has made significant strides in the field of pharmaceuticals with her innovative approaches. With a track record of three patents, she focuses primarily on developing processes that enhance the efficacy of pharmaceutical compounds, particularly those that face solubility issues.

Latest Patents

Among her latest patents, Birgitte has patented a process titled "Controlled Agglomeration." This method facilitates the preparation of particulate materials through controlled growth in particle size. It is specifically designed for pharmaceutical compositions containing therapeutically active substances that possess low aqueous solubility or are prone to chemical degradation. The process involves spraying a carrier composition in liquid form onto a solid material while maintaining appropriate temperatures to ensure optimal particle formation. This innovative method promises to improve the delivery and effectiveness of vital pharmaceutical compounds.

Career Highlights

Birgitte has contributed her expertise to notable organizations within the pharmaceutical industry, including Veloxis Pharmaceuticals A/S and Lifecycle Pharma A/S. Through her work, she has continuously explored ways to enhance pharmaceutical formulations, showcasing her commitment to advancing medical science.

Collaborations

Throughout her career, Birgitte has collaborated with esteemed colleagues such as Per Holm and Jannie Egeskov Holm. These partnerships have fostered an environment of innovation and teamwork, leading to groundbreaking developments in pharmaceutical research.

Conclusion

Birgitte Møllgaard stands out as a pioneering inventor in the pharmaceutical field, with her innovative Controlled Agglomeration method at the forefront of her achievements. Her contributions not only reflect her dedication to improving drug formulations but also represent her role in advancing pharmaceutical technology for better healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…